STAT June 6, 2024
Allison DeAngelis, Adam Feuerstein

How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology meeting surpass expectations?

We discuss that and more in this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article